<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_ISCI101297 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEfx1 jpg ?>
<?FILEmmc1 docx ?>
<?properties open_access?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">iScience</journal-id>
    <journal-id journal-id-type="iso-abbrev">iScience</journal-id>
    <journal-title-group>
      <journal-title>iScience</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2589-0042</issn>
    <publisher>
      <publisher-name>Elsevier</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">7305714</article-id>
    <article-id pub-id-type="publisher-id">S2589-0042(20)30484-3</article-id>
    <article-id pub-id-type="doi">10.1016/j.isci.2020.101297</article-id>
    <article-id pub-id-type="publisher-id">101297</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>CORDITE: The Curated CORona Drug InTERactions Database for SARS-CoV-2</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Martin</surname>
          <given-names>Roman</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Löchel</surname>
          <given-names>Hannah F.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn1" ref-type="fn">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Welzel</surname>
          <given-names>Marius</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Hattab</surname>
          <given-names>Georges</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Hauschild</surname>
          <given-names>Anne-Christin</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Heider</surname>
          <given-names>Dominik</given-names>
        </name>
        <email>dominik.heider@uni-marburg.de</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="fn2" ref-type="fn">3</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>1</label>Department of Mathematics and Computer Science, Philipps-University of Marburg, Hans-Meerwein-Str. 6, 35032 Marburg, Germany</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>Corresponding author <email>dominik.heider@uni-marburg.de</email></corresp>
      <fn id="fn1">
        <label>2</label>
        <p id="ntpara0010">These authors contributed equally</p>
      </fn>
      <fn id="fn2">
        <label>3</label>
        <p id="ntpara0015">Lead Contact</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>6</month>
      <year>2020</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <day>24</day>
      <month>7</month>
      <year>2020</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>20</day>
      <month>6</month>
      <year>2020</year>
    </pub-date>
    <volume>23</volume>
    <issue>7</issue>
    <elocation-id>101297</elocation-id>
    <history>
      <date date-type="received">
        <day>4</day>
        <month>5</month>
        <year>2020</year>
      </date>
      <date date-type="rev-recd">
        <day>9</day>
        <month>6</month>
        <year>2020</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>6</month>
        <year>2020</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2020 The Authors</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <title>Summary</title>
      <p>Since the outbreak in 2019, researchers are trying to find effective drugs against the SARS-CoV-2 virus based on <italic>de novo</italic> drug design and drug repurposing. The former approach is very time consuming and needs extensive testing in humans, whereas drug repurposing is more promising, as the drugs have already been tested for side effects, etc. At present, there is no treatment for COVID-19 that is clinically effective, but there is a huge amount of data from studies that analyze potential drugs.</p>
      <p>We developed CORDITE to efficiently combine state-of-the-art knowledge on potential drugs and make it accessible to scientists and clinicians. The web interface also provides access to an easy-to-use API that allows a wide use for other software and applications, e.g., for meta-analysis, design of new clinical studies, or simple literature search. CORDITE is currently empowering many scientists across all continents and accelerates research in the knowledge domains of virology and drug design.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical Abstract</title>
      <fig id="undfig1" position="anchor">
        <graphic xlink:href="fx1"/>
      </fig>
    </abstract>
    <abstract abstract-type="author-highlights" id="abs0020">
      <title>Highlights</title>
      <p>
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <label>•</label>
            <p id="p0010">CORDITE aggregates all available knowledge on potential drugs for SARS-CoV-2</p>
          </list-item>
          <list-item id="u0015">
            <label>•</label>
            <p id="p0015">CORDITE represents the largest curated database for drugs and interactions</p>
          </list-item>
          <list-item id="u0020">
            <label>•</label>
            <p id="p0020">CORDITE makes the data accessible via a webserver and an open API</p>
          </list-item>
          <list-item id="u0025">
            <label>•</label>
            <p id="p0025">CORDITE enables easy meta-analyses, design of new clinical studies, or literature search</p>
          </list-item>
        </list>
      </p>
    </abstract>
    <abstract abstract-type="teaser" id="abs0025">
      <p>Medicine; Virology; Drugs; Bioinformatics; Biological Database</p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Subject Areas</title>
      <kwd>Medicine</kwd>
      <kwd>Virology</kwd>
      <kwd>Drugs</kwd>
      <kwd>Bioinformatics</kwd>
      <kwd>Biological Database</kwd>
    </kwd-group>
  </article-meta>
  <notes>
    <p id="misc0010">Published: July 24, 2020</p>
  </notes>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p id="p0030">Coronaviruses can cause major outbreaks with fatal pneumonia, e.g., the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 with a fatality rate of around 10% (<xref rid="bib19" ref-type="bibr">Lee et al., 2003</xref>) or the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 with a fatality rate of 35% (<xref rid="bib8" ref-type="bibr">de Groot et al., 2013</xref>). In 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the disease COVID-19 and led to a pandemic (<xref rid="bib33" ref-type="bibr">Zhu et al., 2020</xref>). The common symptoms of COVID-19 include fever, cough, shortness of breath, and dyspnea. A more severe progression of the COVID-19 disease may lead to pneumonia and severe acute respiratory syndromes. Unfortunately, there are no specific drugs or vaccines approved for the treatment of COVID-19 yet (<xref rid="bib15" ref-type="bibr">Huang et al., 2020</xref>).</p>
    <p id="p0035">Traditionally, <italic>de novo</italic> drug design and drug repurposing are the common strategies scientists use to combat viral diseases. However, designing a new drug is very time consuming and needs extensive testing before clinical use in humans. In contrast, the repurposing of approved drugs or drugs in clinical trials is more promising, in particular as these have already been tested for side effects, toxicity, bioavailability, etc. At the moment, there is a huge amount of data from studies that analyze potential drugs based on computer simulations, <italic>in vitro</italic> studies, case studies, or clinical trials. However, none of the proposed treatments for COVID-19 have been proven to be clinically effective yet.</p>
    <p id="p0040">Potential drugs can target viral proteins or human proteins. At the time of writing, the most important viral target molecules that have been investigated for drug repurposing are SARS-CoV-2 spike protein, main protease (3CLpro, Mpro), papain-like proteinase (PLpro), and RNA-dependent RNA polymerase (RdRp) (<xref rid="bib22" ref-type="bibr">Ou et al., 2020</xref>; <xref rid="bib31" ref-type="bibr">Zhang et al., 2020</xref>), whereas the main targets on the human cell membrane are angiotensin-converting enzyme 2 (ACE2) and transmembrane protease serine 2 (TMPRSS2) (<xref rid="bib3" ref-type="bibr">Aronson and Ferner, 2020</xref>). Besides these targets, several other candidates have been investigated as potential targets. Such investigations occurred on both viral and human sides, e.g., the methyltransferase and furin, respectively (<xref rid="bib4" ref-type="bibr">Bestle et al., 2020</xref>; <xref rid="bib18" ref-type="bibr">Khan et al., 2020</xref>). Also, several potential drugs were announced at the beginning of the pandemic, which later proved to be insufficiently effective or even harmful to patients, such as hydroxychloroquine or chloroquine phosphate. For instance, <xref rid="bib10" ref-type="bibr">Gautret et al., 2020</xref> reported a significant decrease in viral load in patients treated with hydroxychloroquine compared with controls. However, others have shown that these potential drugs can have severe side effects such as cardiac toxicity and also increased mortality (<xref rid="bib20" ref-type="bibr">Mehra et al., 2020</xref>). Nevertheless, some of those studies showing higher mortality were later retracted because of a lack of transparency concerning the data (<xref rid="bib21" ref-type="bibr">Mehra et al., 2020b</xref>). Other potential drug candidates, such as a combination of lopinavir with ritonavir (also known as Kaletra), were first considered promising candidates (<xref rid="bib17" ref-type="bibr">Jeon et al., 2020</xref>) but later shown to be ineffective for SARS-CoV-2 (<xref rid="bib5" ref-type="bibr">Cao et al., 2020</xref>). Nevertheless, many new drug candidates have been proposed by using different computational approaches, which address different viral and human targets (<xref rid="bib16" ref-type="bibr">Hufsky et al., 2020</xref>; <xref rid="bib23" ref-type="bibr">Sadegh et al., 2020</xref>).</p>
    <p id="p0045">The SARS-CoV-2 virus uses the human receptor ACE2 for cell entry, which is also used by SARS (<xref rid="bib11" ref-type="bibr">Gralinski and Menachery, 2020</xref>; <xref rid="bib26" ref-type="bibr">Wan et al., 2020</xref>; <xref rid="bib28" ref-type="bibr">Xu et al., 2020</xref>; <xref rid="bib32" ref-type="bibr">Zhou et al., 2020</xref>). It is expressed as a membrane-bound protein in the lungs, heart, kidneys, stomach, spleen, intestine, bone marrow, kidney, liver, brain, testis, and placenta (<xref rid="bib24" ref-type="bibr">Shenoy et al., 2011</xref>; <xref rid="bib9" ref-type="bibr">Donoghue et al., 2000</xref>; <xref rid="bib25" ref-type="bibr">Soler et al., 2008</xref>). Moreover, <xref rid="bib14" ref-type="bibr">Hoffmann et al. (2020)</xref> showed that SARS-CoV-2 depends on TMPRSS2, which therefore can serve as a target in therapy as well. TMPRSS2 primes the spike protein of SARS-Cov-2 to enable cell entry on ACE2. The authors further suggested that ACE2 binding to the spike protein might have a higher affinity compared with SARS. This may explain the infection of the upper respiratory system by SARS-CoV-2, which has not been observed in SARS, because in the upper respiratory system less ACE2 is expressed.</p>
    <p id="p0050">Structurally, each virion is approximately 50–200 nm in diameter (<xref rid="bib6" ref-type="bibr">Chen et al., 2020</xref>). Like other coronaviruses, SARS-CoV-2 has four structural polyproteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The N protein holds the RNA genome, whereas the S, E, and M proteins together are part of the viral envelope. Upon successful attachment of the virus to the membrane of the host cell via the spike protein, the virus fuses with the membrane (<xref rid="bib27" ref-type="bibr">Wu et al., 2020</xref>; <xref rid="bib14" ref-type="bibr">Hoffmann et al., 2020</xref>). Next, the endosome sees a drop in pH and the genomic RNAss(+) is released into the cell's cytoplasm (<xref rid="bib29" ref-type="bibr">Yang et al., 2004</xref>). As shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>, upon uncoating and release of the RNA + sense viral genome in the cytoplasm, the host ribosome translates the viral RNA replicase or the viral RNA-dependent RNA polymerase (RdRp) (<xref rid="bib1" ref-type="bibr">Ahn et al., 2012</xref>; <xref rid="bib30" ref-type="bibr">Yin et al., 2020</xref>). This triggers proteolysis using the main protease of SARS-CoV-2 (also named 3CLpro) and the papain-like proteinase (PLpro) and enables the replicate-transcriptase complex to transcript subgenomic RNAs(+) (<xref rid="bib2" ref-type="bibr">Anand et al., 2003</xref>; <xref rid="bib7" ref-type="bibr">Chen et al., 2014</xref>). Pre-genomic RNAss(−) are replicated into genomic RNAss(+), whereas the former translation of subgenomic RNA(+) results in the aforementioned polyproteins. Essentially, the virus RNA uses the host cell to create new viral RNA genomes and to assemble new viral particles. These are the aforementioned S, E, M, and N structural proteins. They transit to the endoplasmic reticulum and are recruited for the assembly and building of new virions into the Golgi apparatus and burgeon out of the apparatus to then form mature virions (<xref rid="bib12" ref-type="bibr">Guo et al., 2020</xref>). The N protein allows the viral genome to be extremely tightly packed into future viral capsids. In the end, new virions are released out of the host cell to infiltrate other cells in the host organism (<xref rid="bib13" ref-type="bibr">He et al., 2020</xref>). A simplified illustration of the replication cycle of the SARS-CoV-2 virus is shown in <xref rid="fig1" ref-type="fig">Figure 1</xref>.<fig id="fig1"><label>Figure 1</label><caption><p>Overview of the Replication Cycle of SARS-CoV2 Inside a Human Cell</p><p>The main targets that are investigated for drug repurposing are reported.</p></caption><graphic xlink:href="gr1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Depiction of All Processing Steps within the CORDITE Workflow.</p><p>(A) Literature aggregation.</p><p>(B) database curation.</p><p>(C) web interface.</p></caption><graphic xlink:href="gr2"/></fig></p>
    <p id="p0055">The knowledge from the life cycle of the SARS-CoV-2 virus offers a great potential to find suitable drugs for the already known targets. To combine the large amounts of current knowledge, we centralize the aggregated information from published articles and preprints about potential drugs, targets, and their interactions into CORDITE (CORona Drug InTEractions database), which includes a web interface and an application programming interface (API).</p>
  </sec>
  <sec id="sec2">
    <title>Results</title>
    <p id="p0060">CORDITE integrates many functionalities to enable users to access, sort, and download relevant data to conduct meta-analyses, to design new clinical trials, or even to conduct a curated literature search. CORDITE automatically incorporates publications from PubMed (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/" id="intref0010">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link>), bioRxiv (<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/" id="intref0015">https://www.biorxiv.org/</ext-link>), chemRxiv (<ext-link ext-link-type="uri" xlink:href="https://www.chemrxiv.org/" id="intref0020">https://www.chemrxiv.org/</ext-link>), and medRxiv (<ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/" id="intref0025">https://www.medrxiv.org/</ext-link>) that report information on computational, <italic>in vitro</italic>, or case studies on potential drugs for COVID-19 (see <xref rid="fig2" ref-type="fig">Figure 2</xref>). Besides original research, we also included reviews and comments in the database. The information from the articles and preprints are manually curated by moderators and can be accessed via the web interface or the open API. Users can directly access the publications, interactions, drugs, targets, and clinical trials. The interactions and the effectiveness of certain drugs are also shown as positive/negative results in a transparent way. Thus, the user can easily see the contradictory results of different studies and can take these into account for, e.g., meta-analyses. This access may offer easier integration for future software or apps that may need curated data.</p>
    <p id="p0065">Moreover, we include registered clinical trials from the National Institutes of Health (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/" id="intref0030">https://clinicaltrials.gov/</ext-link>) for COVID-19. The CORDITE database is updated through manual curation. The current summary for interactions, drugs, etc., is reported in <xref rid="tbl1" ref-type="table">Table 1</xref>. An introductory video for the use of CORDITE can be found on the website.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Summary Table of all Entry Types at Date of Submission</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Type</th><th>Numbers</th></tr></thead><tbody><tr><td>Interactions</td><td align="char">849</td></tr><tr><td>Targets</td><td align="char">25</td></tr><tr><td>Drugs</td><td align="char">639</td></tr><tr><td>Publications</td><td align="char">324</td></tr><tr><td>Clinical trials</td><td align="char">247</td></tr></tbody></table></table-wrap></p>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p id="p0070">CORDITE provides an easy-to-use web interface and also access to an easy-to-use API that allows a wide use for other software and applications, e.g., for meta-analysis, design of new clinical studies, or simple literature search. CORDITE is currently the largest curated database for drug interactions for SARS-CoV-2, and therefore it offers the opportunity to accelerate research in the knowledge domains of virology and drug design. Because of the popularity and impact of the CORDITE website and database, we plan to continue hosting and managing CORDITE throughout the COVID-19 pandemic. Moreover, we will continuously improve the website and database to establish a standard tool for future diseases. We believe our efforts are essential to help researchers and clinicians to get an overview of existing studies and to accelerate the global search for new treatments.</p>
    <sec id="sec3.1">
      <title>Limitations of the Study</title>
      <p id="p0075">CORDITE aggregates available knowledge on drugs for COVID-19; however, in particular the preprints have not been peer reviewed. Thus, CORDITE cannot guarantee the reliability of the studies and their results, in particular the effectiveness of the drugs.</p>
    </sec>
    <sec id="sec3.2">
      <title>Resource Availability</title>
      <sec id="sec3.2.1">
        <title>Lead Contact</title>
        <p id="p0080">Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Dominik Heider (<ext-link ext-link-type="uri" xlink:href="mailto:dominik.heider@uni-marburg.de" id="intref0035">dominik.heider@uni-marburg.de</ext-link>).</p>
      </sec>
      <sec id="sec3.2.2">
        <title>Materials Availability</title>
        <p id="p0085">This study did not generate new unique data.</p>
      </sec>
      <sec sec-type="data-availability" id="sec3.2.3">
        <title>Data and Code Availability</title>
        <p id="p0090">This study did not generate data. The curated data can be accessed freely via the API.</p>
        <p id="p0095">Availability: CORDITE is available at <ext-link ext-link-type="uri" xlink:href="http://cordite.mathematik.uni-marburg.de" id="intref0040">https://cordite.mathematik.uni-marburg.de</ext-link>.</p>
      </sec>
    </sec>
  </sec>
  <sec id="sec4">
    <title>Methods</title>
    <p id="p0100">All methods can be found in the accompanying <xref rid="mmc1" ref-type="supplementary-material">Transparent Methods supplemental file</xref>.</p>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Ahn</surname>
            <given-names>D.G.</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>J.K.</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Oh</surname>
            <given-names>J.W.</given-names>
          </name>
        </person-group>
        <article-title>Biochemical characterization of a recombinant SARS coronavirus nsp12 RNA-dependent RNA polymerase capable of copying viral RNA templates</article-title>
        <source>Arch. Virol.</source>
        <volume>157</volume>
        <year>2012</year>
        <fpage>2095</fpage>
        <lpage>2104</lpage>
        <pub-id pub-id-type="pmid">22791111</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Anand</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Ziebuhr</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wadhwani</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mesters</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Hilgenfeld</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs</article-title>
        <source>Science</source>
        <volume>300</volume>
        <year>2003</year>
        <fpage>1763</fpage>
        <lpage>1767</lpage>
        <pub-id pub-id-type="pmid">12746549</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Aronson</surname>
            <given-names>J.K.</given-names>
          </name>
          <name>
            <surname>Ferner</surname>
            <given-names>R.E.</given-names>
          </name>
        </person-group>
        <article-title>Drugs and the renin-angiotensin system in covid-19</article-title>
        <source>BMJ</source>
        <volume>369</volume>
        <year>2020</year>
        <fpage>m1313</fpage>
        <pub-id pub-id-type="pmid">32241880</pub-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Bestle</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Heindl</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Limburg</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Lam</surname>
            <given-names>van T.V.</given-names>
          </name>
          <name>
            <surname>Pilgram</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Moulton</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Hardes</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Eickmann</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Dolnik</surname>
            <given-names>O.</given-names>
          </name>
        </person-group>
        <article-title>TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets</article-title>
        <source>BioRxiv</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1101/2020.04.15.042085</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Cao</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Ruan</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19</article-title>
        <source>N. Engl. J. Med.</source>
        <volume>382</volume>
        <year>2020</year>
        <fpage>1787-1799</fpage>
        <pub-id pub-id-type="pmid">32187464</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Qu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Gong</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Qiu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wei</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>
        <source>Lancet</source>
        <volume>395</volume>
        <year>2020</year>
        <fpage>507</fpage>
        <lpage>513</lpage>
        <pub-id pub-id-type="pmid">32007143</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Xing</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex</article-title>
        <source>Protein Cell</source>
        <volume>5</volume>
        <year>2014</year>
        <fpage>369</fpage>
        <lpage>381</lpage>
        <pub-id pub-id-type="pmid">24622840</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>de Groot</surname>
            <given-names>R.J.</given-names>
          </name>
          <name>
            <surname>Baker</surname>
            <given-names>S.C.</given-names>
          </name>
          <name>
            <surname>Baric</surname>
            <given-names>R.S.</given-names>
          </name>
          <name>
            <surname>Brown</surname>
            <given-names>C.S.</given-names>
          </name>
          <name>
            <surname>Drosten</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Enjuanes</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Fouchier</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Galiano</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Gorbalenya</surname>
            <given-names>A.E.</given-names>
          </name>
          <name>
            <surname>Memish</surname>
            <given-names>Z.A.</given-names>
          </name>
        </person-group>
        <article-title>Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group</article-title>
        <source>J. Virol.</source>
        <volume>87</volume>
        <year>2013</year>
        <fpage>7790</fpage>
        <lpage>7792</lpage>
        <pub-id pub-id-type="pmid">23678167</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Donoghue</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Hsieh</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Baronas</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Godbout</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Gosselin</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Stagliano</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Donovan</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Woolf</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Robison</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Jeyaseelan</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9</article-title>
        <source>Circ. Res.</source>
        <volume>87</volume>
        <year>2000</year>
        <fpage>E1</fpage>
        <lpage>E9</lpage>
        <pub-id pub-id-type="pmid">10969042</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Gautret</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Lagier</surname>
            <given-names>J.C.</given-names>
          </name>
          <name>
            <surname>Parola</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Hoang</surname>
            <given-names>V.T.</given-names>
          </name>
          <name>
            <surname>Meddeb</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Mailhe</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Doudier</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Courjon</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Giordanengo</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Vieira</surname>
            <given-names>V.E.</given-names>
          </name>
        </person-group>
        <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title>
        <source>Int. J. Antimicrob. Agents</source>
        <year>2020</year>
        <ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/32205204/" id="interref0020">https://pubmed.ncbi.nlm.nih.gov/32205204/</ext-link>
      </element-citation>
    </ref>
    <ref id="bib11">
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Gralinski</surname>
            <given-names>L.E.</given-names>
          </name>
          <name>
            <surname>Menachery</surname>
            <given-names>V.D.</given-names>
          </name>
        </person-group>
        <article-title>Return of the coronavirus: 2019-nCoV</article-title>
        <source>Viruses</source>
        <volume>12</volume>
        <year>2020</year>
        <fpage>E135</fpage>
        <pub-id pub-id-type="pmid">31991541</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>Y.R.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>Q.D.</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>Z.S.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>Y.Y.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>S.D.</given-names>
          </name>
          <name>
            <surname>Jin</surname>
            <given-names>H.J.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>K.S.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>D.Y.</given-names>
          </name>
          <name>
            <surname>Yan</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak–an update on the status</article-title>
        <source>Mil. Med. Res.</source>
        <volume>7</volume>
        <year>2020</year>
        <fpage>11</fpage>
        <pub-id pub-id-type="pmid">32169119</pub-id>
      </element-citation>
    </ref>
    <ref id="bib13">
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>He</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Deng</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>W.</given-names>
          </name>
        </person-group>
        <article-title>Coronavirus disease 2019: what we know?</article-title>
        <source>J. Med. Virol.</source>
        <volume>92</volume>
        <year>2020</year>
        <fpage>719</fpage>
        <lpage>725</lpage>
        <pub-id pub-id-type="pmid">32170865</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Hoffmann</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Kleine-Weber</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Schroeder</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Krüger</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Herrler</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Erichsen</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Schiergens</surname>
            <given-names>T.S.</given-names>
          </name>
          <name>
            <surname>Herrler</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>N.H.</given-names>
          </name>
          <name>
            <surname>Nitsche</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>
        <source>Cell</source>
        <volume>181</volume>
        <year>2020</year>
        <fpage>271</fpage>
        <lpage>280</lpage>
        <pub-id pub-id-type="pmid">32142651</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Fan</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Gu</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>
        <source>Lancet</source>
        <volume>395</volume>
        <year>2020</year>
        <fpage>497</fpage>
        <lpage>506</lpage>
        <pub-id pub-id-type="pmid">31986264</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Hufsky</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Lamkiewicz</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Almeida</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Aouacheria</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Arighi</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Bateman</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Baumbach</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Beerenwinkel</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Brandt</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Cacciabue</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Computational strategies to combat COVID-19: useful tools to accelerate SARS-CoV-2 and coronavirus research</article-title>
        <source>Preprint</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.20944/preprints202005.0376.v1</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Jeon</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Ko</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Byun</surname>
            <given-names>S.Y.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Shum</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs</article-title>
        <source>Antimicrob. Agents Chemother.</source>
        <volume>64</volume>
        <year>2020</year>
        <fpage>e00819-20</fpage>
        <pub-id pub-id-type="pmid">32366720</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>R.J.</given-names>
          </name>
          <name>
            <surname>Jha</surname>
            <given-names>R.K.</given-names>
          </name>
          <name>
            <surname>Amera</surname>
            <given-names>G.M.</given-names>
          </name>
          <name>
            <surname>Jain</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Pathak</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>R.P.</given-names>
          </name>
          <name>
            <surname>Muthukumaran</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>A.K.</given-names>
          </name>
        </person-group>
        <article-title>Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2'-O-ribose methyltransferase</article-title>
        <source>J. Biomol. Struct. Dyn.</source>
        <volume>20</volume>
        <year>2020</year>
        <fpage>1</fpage>
        <lpage>14</lpage>
      </element-citation>
    </ref>
    <ref id="bib19">
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Hui</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Cameron</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Joynt</surname>
            <given-names>G.M.</given-names>
          </name>
          <name>
            <surname>Ahuja</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Yung</surname>
            <given-names>M.Y.</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>C.B.</given-names>
          </name>
          <name>
            <surname>To</surname>
            <given-names>K.F.</given-names>
          </name>
        </person-group>
        <article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title>
        <source>N. Engl. J. Med.</source>
        <volume>348</volume>
        <year>2003</year>
        <fpage>1986</fpage>
        <lpage>1994</lpage>
        <pub-id pub-id-type="pmid">12682352</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Mehra</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Desai</surname>
            <given-names>S.S.</given-names>
          </name>
          <name>
            <surname>Ruschitzka</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>A.N.</given-names>
          </name>
        </person-group>
        <article-title>Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</article-title>
        <source>Lancet</source>
        <year>2020</year>
        <ext-link ext-link-type="uri" xlink:href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext" id="interref0010">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext</ext-link>
      </element-citation>
    </ref>
    <ref id="bib21">
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Mehra</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Ruschitzka</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>A.N.</given-names>
          </name>
        </person-group>
        <article-title>Retraction—hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</article-title>
        <source>Lancet</source>
        <year>2020</year>
        <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31324-6</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Ou</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mi</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Ren</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title>
        <source>Nat. Commun.</source>
        <volume>11</volume>
        <year>2020</year>
        <fpage>1620</fpage>
        <pub-id pub-id-type="pmid">32221306</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Sadegh</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Matschinske</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Blumenthal</surname>
            <given-names>D.B.</given-names>
          </name>
          <name>
            <surname>Galindez</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Kacprowski</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>List</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Nasirigerdeh</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Oubounyt</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Pichlmair</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Rose</surname>
            <given-names>T.D.</given-names>
          </name>
          <name>
            <surname>Salgado-Albarrán</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing</article-title>
        <source>arXiv</source>
        <year>2020</year>
        <ext-link ext-link-type="uri" xlink:href="https://arxiv.org/abs/2004.12420" id="interref0015">https://arxiv.org/abs/2004.12420</ext-link>
      </element-citation>
    </ref>
    <ref id="bib24">
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Shenoy</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Qi</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Katovich</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Raizada</surname>
            <given-names>M.K.</given-names>
          </name>
        </person-group>
        <article-title>ACE2, a promising therapeutic target for pulmonary hypertension</article-title>
        <source>Curr. Opin. Pharmacol.</source>
        <volume>11</volume>
        <year>2011</year>
        <fpage>150</fpage>
        <lpage>155</lpage>
        <pub-id pub-id-type="pmid">21215698</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Soler</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Barrios</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Oliva</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Batlle</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>Pharmacologic modulation of ACE2 expression</article-title>
        <source>Curr. Hypertens. Rep.</source>
        <volume>10</volume>
        <year>2008</year>
        <fpage>410</fpage>
        <lpage>414</lpage>
        <pub-id pub-id-type="pmid">18775121</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Wan</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Shang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Graham</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Baric</surname>
            <given-names>R.S.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>F.</given-names>
          </name>
        </person-group>
        <article-title>Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title>
        <source>J. Virol.</source>
        <volume>94</volume>
        <year>2020</year>
        <comment>e00127–20</comment>
      </element-citation>
    </ref>
    <ref id="bib27">
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Wu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Zhong</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods</article-title>
        <source>Acta Pharm. Sin B</source>
        <volume>10</volume>
        <year>2020</year>
        <fpage>766</fpage>
        <lpage>788</lpage>
      </element-citation>
    </ref>
    <ref id="bib28">
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Feng</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhong</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Hao</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission</article-title>
        <source>Sci. China Life Sci.</source>
        <volume>63</volume>
        <year>2020</year>
        <fpage>457</fpage>
        <lpage>460</lpage>
        <pub-id pub-id-type="pmid">32009228</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Yang</surname>
            <given-names>Z.Y.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ganesh</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>W.P.</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Subbarao</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Nabel</surname>
            <given-names>G.J.</given-names>
          </name>
        </person-group>
        <article-title>pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN</article-title>
        <source>J. Virol.</source>
        <volume>78</volume>
        <year>2004</year>
        <fpage>5642</fpage>
        <lpage>5650</lpage>
        <pub-id pub-id-type="pmid">15140961</pub-id>
      </element-citation>
    </ref>
    <ref id="bib30">
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Yin</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Mao</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Luan</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>D.D.</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir</article-title>
        <source>Science</source>
        <volume>368</volume>
        <year>2020</year>
        <fpage>1499</fpage>
        <lpage>1504</lpage>
        <pub-id pub-id-type="pmid">32358203</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Sun</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Curth</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Drosten</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Sauerhering</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Becker</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Rox</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Hilgenfeld</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors</article-title>
        <source>Science</source>
        <volume>368</volume>
        <year>2020</year>
        <fpage>409</fpage>
        <lpage>412</lpage>
        <pub-id pub-id-type="pmid">32198291</pub-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>X.L.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.G.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Si</surname>
            <given-names>H.R.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C.L.</given-names>
          </name>
        </person-group>
        <article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
        <source>Nature</source>
        <volume>579</volume>
        <year>2020</year>
        <fpage>270</fpage>
        <lpage>273</lpage>
        <pub-id pub-id-type="pmid">32015507</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>R.</given-names>
          </name>
        </person-group>
        <article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>
        <source>N. Engl. J. Med.</source>
        <volume>382</volume>
        <year>2020</year>
        <fpage>727</fpage>
        <lpage>733</lpage>
        <pub-id pub-id-type="pmid">31978945</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec2" sec-type="supplementary-material">
    <title>Supplemental Information</title>
    <p id="p0125">
      <supplementary-material content-type="local-data" id="mmc1">
        <caption>
          <title>Document S1. Transparent Methods</title>
        </caption>
        <media xlink:href="mmc1.docx"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p>The authors thank Hagen Dreβler for technical assistance.</p>
    <sec id="sec5">
      <title>Author Contributions</title>
      <p id="p0110">R.M. developed and implemented the database and the API. H.F.L. developed and implemented the web interface and curated approximately 2.3% of the data. M.W. developed the automated literature crawler and curated approximately 11.3% of the data. G.H. created <xref rid="fig1" ref-type="fig">Figure 1</xref> and the visual identity of the web interface and contributed to the initial draft. A.-C.H. contributed to the project design, created <xref rid="fig2" ref-type="fig">Figure 2</xref>, and curated approximately 7.4% of the data. D.H. designed and supervised the project, wrote the manuscript, and curated approximately 79.0% of the data. All authors revised the final manuscript.</p>
    </sec>
    <sec sec-type="COI-statement" id="sec6">
      <title>Declaration of Interests</title>
      <p id="p0115">The authors declare no competing interests.</p>
    </sec>
  </ack>
  <fn-group>
    <fn id="appsec1" fn-type="supplementary-material">
      <p id="p0120">Supplemental Information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.isci.2020.101297" id="intref0045">https://doi.org/10.1016/j.isci.2020.101297</ext-link>.</p>
    </fn>
  </fn-group>
</back>
